190 related articles for article (PubMed ID: 26283036)
21. Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG).
Kasper B; Gruenwald V; Reichardt P; Bauer S; Rauch G; Limprecht R; Sommer M; Dimitrakopoulou-Strauss A; Pilz L; Haller F; Hohenberger P
Eur J Cancer; 2017 May; 76():60-67. PubMed ID: 28282612
[TBL] [Abstract][Full Text] [Related]
22. Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database.
Stacchiotti S; Provenzano S; Dagrada G; Negri T; Brich S; Basso U; Brunello A; Grosso F; Galli L; Palassini E; Libertini M; Colia V; Gronchi A; Dei Tos AP; Crippa F; Morosi C; Pilotti S; Casali PG
Ann Surg Oncol; 2016 Sep; 23(9):2735-44. PubMed ID: 27334221
[TBL] [Abstract][Full Text] [Related]
23. [Advanced dermatofibrosarcoma protuberans treated with imatinib mesylate].
Zhu JH; Li QW; Xiao WH; Sun JZ; Wang RL; Lu JY
Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):470-2. PubMed ID: 21875491
[TBL] [Abstract][Full Text] [Related]
24. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib.
Tielen R; Verhoef C; van Coevorden F; Gelderblom H; Sleijfer S; Hartgrink HH; Bonenkamp JJ; van der Graaf WT; de Wilt JH
Eur J Surg Oncol; 2013 Feb; 39(2):150-5. PubMed ID: 23084087
[TBL] [Abstract][Full Text] [Related]
25. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
Wyman K; Atkins MB; Prieto V; Eton O; McDermott DF; Hubbard F; Byrnes C; Sanders K; Sosman JA
Cancer; 2006 May; 106(9):2005-11. PubMed ID: 16565971
[TBL] [Abstract][Full Text] [Related]
26. Response to imatinib plus sirolimus in advanced chordoma.
Stacchiotti S; Marrari A; Tamborini E; Palassini E; Virdis E; Messina A; Crippa F; Morosi C; Gronchi A; Pilotti S; Casali PG
Ann Oncol; 2009 Nov; 20(11):1886-94. PubMed ID: 19570961
[TBL] [Abstract][Full Text] [Related]
27. Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center.
Afshar M; Pascoe J; Whitmarsh S; James N; Porfiri E
Drug Des Devel Ther; 2015; 9():13-9. PubMed ID: 25552898
[TBL] [Abstract][Full Text] [Related]
28. Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers.
Flaherty KT; Hamilton BK; Rosen MA; Amaravadi RK; Schuchter LM; Gallagher M; Chen H; Sehgal C; O'Dwyer PJ
Oncologist; 2015 Aug; 20(8):952-9. PubMed ID: 26084808
[TBL] [Abstract][Full Text] [Related]
29. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma.
Chugh R; Dunn R; Zalupski MM; Biermann JS; Sondak VK; Mace JR; Leu KM; Chandler WF; Baker LH
J Clin Oncol; 2005 May; 23(15):3597-604. PubMed ID: 15908670
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response.
Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Sohn HJ; Lee JS; Kang YK
Jpn J Clin Oncol; 2006 Nov; 36(11):704-11. PubMed ID: 17068083
[TBL] [Abstract][Full Text] [Related]
32. The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses.
Park SJ; Ryu MH; Ryoo BY; Park YS; Sohn BS; Kim HJ; Kim CW; Kim KH; Yu CS; Yook JH; Kim BS; Kang YK
Ann Surg Oncol; 2014 Dec; 21(13):4211-7. PubMed ID: 24980089
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube.
Noguera IR; Sun CC; Broaddus RR; Branham D; Levenback CF; Ramirez PT; Sood AK; Coleman RL; Gershenson DM
Gynecol Oncol; 2012 Jun; 125(3):640-5. PubMed ID: 22387451
[TBL] [Abstract][Full Text] [Related]
34. Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas.
Orzan F; Terreni MR; Longoni M; Boari N; Mortini P; Doglioni C; Riva P
Oncol Rep; 2007 Jul; 18(1):249-52. PubMed ID: 17549375
[TBL] [Abstract][Full Text] [Related]
35. Treatment of gastrointestinal stromal tumor with imatinib mesylate: a retrospective single-center experience in Heidelberg.
Kasper B; Kallinowski B; Herrmann T; Lehnert T; Mechtersheimer G; Geer T; Ho AD; Egerer G
Dig Dis; 2006; 24(1-2):207-11. PubMed ID: 16699280
[TBL] [Abstract][Full Text] [Related]
36. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas.
Tamborini E; Miselli F; Negri T; Lagonigro MS; Staurengo S; Dagrada GP; Stacchiotti S; Pastore E; Gronchi A; Perrone F; Carbone A; Pierotti MA; Casali PG; Pilotti S
Clin Cancer Res; 2006 Dec; 12(23):6920-8. PubMed ID: 17145809
[TBL] [Abstract][Full Text] [Related]
37. [Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].
Shen L; Jin ML
Zhonghua Zhong Liu Za Zhi; 2004 Nov; 26(11):697-9. PubMed ID: 15777512
[TBL] [Abstract][Full Text] [Related]
38. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).
Sym SJ; Ryu MH; Lee JL; Chang HM; Kim TW; Kim HC; Kim KH; Yook JH; Kim BS; Kang YK
J Surg Oncol; 2008 Jul; 98(1):27-33. PubMed ID: 18452195
[TBL] [Abstract][Full Text] [Related]
39. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
McArthur GA; Demetri GD; van Oosterom A; Heinrich MC; Debiec-Rychter M; Corless CL; Nikolova Z; Dimitrijevic S; Fletcher JA
J Clin Oncol; 2005 Feb; 23(4):866-73. PubMed ID: 15681532
[TBL] [Abstract][Full Text] [Related]
40. Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study.
Kang HJ; Ryu MH; Kim KM; Park YS; Choi J; Ryoo BY; Kim WH; Im SA; Bang YJ; Park SH; Lee JH; Chung IJ; Bae HI; Kim JG; Lee KH; Song HS; Kwon HC; Baek JH; Shin DB; Lee KE; Kang YK
Acta Oncol; 2012 Apr; 51(4):528-36. PubMed ID: 22150077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
